拉莫三嗪作为难治性癫痫和智力发育迟缓儿童及青少年的附加用药：一项开放性试验。

Lamotrigine as add-on drug in children and adolescents with refractory epilepsy and mental delay: an open trial.

作者信息

Coppola G, Pascotto A

机构信息

Child Neuropsychiatry Clinic, Department of Pediatrics, Second University of Naples, Italy.

出版信息

Brain Dev. 1997 Sep;19(6):398-402. doi: 10.1016/s0387-7604(97)00046-6.

DOI:10.1016/s0387-7604(97)00046-6

PMID:9339867

Abstract

We report the results of an open trial with lamotrigine (LTG) as add-on drug in children and adolescents with refractory epilepsy and mental delay. Thirty-seven outpatients received LTG for a median period of 7 months at a daily dose of 5 and 15 mg/kg in valproate and non-valproate patients, respectively. The total number of seizures decreased by 100% in eight patients (21.6%) and by >50% in five patients (13.5%). However, the number of seizures remained unchanged in 20 patients (54.1%) and increased in four (10.8%). Lamotrigine was more effective in patients with typical and atypical absences, and in patients affected by atonic seizures. Six children (16.2%) developed generally mild adverse side-effects suggesting that LTG is well tolerated.

摘要

我们报告了一项开放试验的结果，该试验将拉莫三嗪（LTG）作为附加药物用于患有难治性癫痫和智力发育迟缓的儿童及青少年。37名门诊患者接受了LTG治疗，丙戊酸盐治疗的患者和非丙戊酸盐治疗的患者每日剂量分别为5和15mg/kg，中位治疗期为7个月。8名患者（21.6%）癫痫发作总数减少了100%，5名患者（13.5%）减少了>50%。然而，20名患者（54.1%）的癫痫发作次数保持不变，4名患者（10.8%）的发作次数增加。拉莫三嗪对典型和非典型失神发作的患者以及失张力发作的患者更有效。6名儿童（16.2%）出现了一般较为轻微的不良反应，这表明LTG耐受性良好。